{"id":3551,"date":"2026-10-01T09:00:00","date_gmt":"2026-10-01T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3551"},"modified":"2026-10-01T19:51:43","modified_gmt":"2026-10-01T23:51:43","slug":"fhd-909-stops-before-expansion","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3551","title":{"rendered":"FHD-909 Stops Before Expansion"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Foghorn Therapeutics \/ Eli Lilly<\/p>\n

Event Type<\/strong><\/p>\n

Clinical \/ Portfolio Discontinuation<\/p>\n

Modality<\/strong><\/p>\n

Small Molecule Allosteric ATPase Inhibitor<\/p>\n

Asset<\/strong><\/p>\n

FHD-909 (LY4050784)<\/p>\n

Target<\/strong><\/p>\n

SMARCA2\/BRM<\/p>\n

Disease Area<\/strong><\/p>\n

SMARCA4-Deficient Non-Small-Cell Lung Cancer<\/p>\n

Summary<\/h4>\n

Foghorn and Lilly will not advance the Phase 1 SMARCA2 inhibitor FHD-909 into expansion and will also stop their selective SMARCA2 degrader program. Foghorn disclosed an approximately 40% workforce reduction and said it will focus on wholly owned EP300 and CBP degrader and other programs. No numerical tumor-response dataset accompanied the announcement.<\/p>\n

Management said FHD-909 achieved selective target inhibition at exposures exceeding preclinical targets with a favorable reported safety profile, yet SMARCA2\/SMARCA4 synthetic lethality did not translate into the efficacy threshold required for advancement. FHD-909 is an oral allosteric ATPase inhibitor, not a degrader. The distinct partnered SMARCA2 degrader also will not progress. The company projects the restructure will extend cash runway into the second half of 2029; that is guidance, not an observed balance-sheet outcome. Foghorn and Lilly do not anticipate further collaboration activity.<\/p>\n

Deep Analysis<\/h4>\n

SMARCA4-deficient non-small-cell lung cancer offers a strong synthetic-lethality rationale for targeting paralog SMARCA2, but clinical tumor dependence may be less complete than cell-line models suggest. Without cohort size, response rates, dose intensity, target-occupancy biomarkers or resistance biopsies, the failure cannot be assigned to target biology alone. Pharmacology in tumors, patient selection and pathway adaptation remain plausible alternatives. The decision to stop both inhibition and degradation increases concern about the therapeutic window or target hypothesis, but does not prove that every SMARCA2 strategy is futile. The layoff reduces operating capacity even as it may lengthen runway; execution plans and severance charges have not been quantified here.<\/p>\n

Interpretation A: the SMARCA2\/4 dependency was too weak in the treated population; the company’s explicit efficacy statement and dual-program termination support this. Contrary evidence is the lack of detailed patient-level efficacy or tumor pharmacodynamics. Interpretation B: trial selection, dosing or agent-specific biology prevented a viable target from showing activity. Reported exposure above preclinical targets does not exclude insufficient intratumoral effect, but simultaneous cancellation of the degrader weakens the agent-only explanation. Biomarker-stratified responses, biopsy target inhibition, exposure-response and competitor data would resolve the distinction.<\/p>\n

Company and Product Background<\/h4>\n

Foghorn researches chromatin dependencies. FHD-909 (LY4050784) allosterically inhibits the SMARCA2\/BRM ATPase in the BAF remodeling complex while seeking selectivity over SMARCA4\/BRG1. In SMARCA4-deficient tumors, SMARCA2 may provide residual remodeling function. The separately discontinued SMARCA2 degrader was a distinct modality; EP300 and CBP degraders remain in Foghorn’s proprietary pipeline.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • FHD-909 Phase 1 dose escalation will not enter expansion; no response table disclosed.<\/li>\n
  • Partnered selective SMARCA2 degrader program also ends.<\/li>\n
  • Approximately 40% workforce reduction; projected runway to H2 2029.<\/li>\n
  • Future evidence: full clinical dataset and independent SMARCA2-modality readouts.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    This is a genuine negative clinical and portfolio signal for the Foghorn-Lilly SMARCA2 effort, with direct organizational consequences. It should temper claims that genetic synthetic lethality necessarily transfers into human efficacy, while leaving the broader chromatin and induced-proximity portfolio unjudged.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 5 of 5. Signal Direction: negative for FHD-909 and the SMARCA2 collaboration; uncertain for Foghorn’s remaining platform. Confidence in Facts: high. Confidence in Interpretation: moderate-low because no full clinical efficacy or pharmacodynamic dataset is public. Red-team conclusion: management’s biological explanation is a hypothesis, not a demonstrated causal decomposition.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Foghorn and Lilly will not advance the Phase 1 SMARCA2 inhibitor FHD-909 into expansion and will also stop their selective SMARCA2 degrader program. Foghorn disclosed an approximately 40% workforce reduction and said it will…<\/p>\n","protected":false},"author":1,"featured_media":3561,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[92,898,896],"class_list":["post-3551","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-eli-lilly","tag-foghorn-therapeutics","tag-therapeutic-indication"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3551","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3551"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3551\/revisions"}],"predecessor-version":[{"id":3566,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3551\/revisions\/3566"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3561"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3551"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3551"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3551"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}